Análisis de la codelección 1p19q en pacientes con diagnóstico de oligodendroglioma y oligoastrocitoma por técnica de CISH
(chromogenic in situ hybridization)
DOI:
https://doi.org/10.56969/oc.v17i4.124Palabras clave:
oligodendroglioma, oligoastrocitoma, delección, FISH, CISH, mixed oligodendroglioma astrocytoma, deletionResumen
En pacientes con diagnóstico de oligodendroglioma (OD) y oligoastrocitoma (OA) la presencia de la codelección 1p19q presenta valor pronóstico y predictivo y se encuentra presente en alrededor del 50% de los casos. La técnica FISH (fluorescence in situ hybridization) es el método estándar para su evaluación. La técnica CISH (chromogenic in situ hybridization) es una alternativa y fue validada en otras neoplasias. Se analizaron las características histológicas de los pacientes con diagnóstico de OD y OA y su correlación con la codelección 1p19q detectada por CISH. En 3 de los 24 pacientes analizados (13%) se encontró la presencia de la codelección 1p19q. Sólo encontramos la codelección en aquellos con diagnóstico de OD grado II. No fue encontrada la mutación en ningún caso en: OD grado III y OA grado II y III. La frecuencia de detección de la codelección (13%) es inferior a la descripta en otros estudios que utilizaron la técnica de FISH. Las posibles causas de esta discordancia pueden atribuirse a que la cantidad de pacientes es insuficiente para validar el método, a errores en el procesamiento del material o en su lectura, o bien a que el método de CISH no es coincidente con FISH.
Citas
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492–507. DOI: https://doi.org/10.1056/NEJMra0708126
Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 2006; 24: 1246–52. DOI: https://doi.org/10.1200/JCO.2005.04.9874
Kamiya M, Nakazato Y. The expression of cell cycle regulatory proteins in oligodendroglial tumors. Clin Neuropathol 2002; 21: 52-65.
Yan H, Williams Parsons D, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–73. DOI: https://doi.org/10.1056/NEJMoa0808710
Fröhling S, Döhner H. Chromosomal abnormalities in cancer. N Engl J Med 2008; 359: 722-34. DOI: https://doi.org/10.1056/NEJMra0803109
Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25: 4127-36. DOI: https://doi.org/10.1200/JCO.2007.11.8554
Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006; 24: 4746–53. DOI: https://doi.org/10.1200/JCO.2006.06.3891
Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24: 2707-14. DOI: https://doi.org/10.1200/JCO.2005.04.3414
van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-22. DOI: https://doi.org/10.1200/JCO.2005.04.6078
Cairncross G, Wang M, Shaw E, et al. Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. J Clin Oncol 2012; 30 (suppl; abstr 2008b). DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.2008b
van den Bent MJ, Xuan KH, Brandes AA, et al. Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). J Clin Oncol 2012; 30 (suppl; abstr 2). DOI: https://doi.org/10.1200/jco.2012.30.18_suppl.2
Marquez A, Wu R, Zhao J, Tao J, Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and inmunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 2004; 13:1-8. DOI: https://doi.org/10.1097/00019606-200403000-00001
Järvelä S, Helin H, Haapasalo J, et al. Amplification of the epidermal growth factor receptor in astrocytic tumors by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol and Appl Neurobiol 2006; 32 441-50. DOI: https://doi.org/10.1111/j.1365-2990.2006.00758.x
Dandanchi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002; 82: 1007-14. DOI: https://doi.org/10.1097/01.LAB.0000024360.48464.A4
Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003; 119: 381-7. DOI: https://doi.org/10.1309/P40P2EAD42PUKDMG
Eberhard DA, Giaccone G, Johnson BE, Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non–Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 983–94. DOI: https://doi.org/10.1200/JCO.2007.12.9858
Shaw E, Arusell R, Scheithauer B, et al. Prospective ran- domized trial of low- versus high-dose radiation therapy in adults with supratentorial lowgrade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20: 2267-76. DOI: https://doi.org/10.1200/JCO.2002.09.126
Buckner JC, Gesme D Jr, O ́Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003; 21: 251-5. DOI: https://doi.org/10.1200/JCO.2003.06.023
Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-45. DOI: https://doi.org/10.1200/JCO.2000.18.3.636
Mokhtari K, Ducray F, Kros JM, et al. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. Cancer 2011; 117: 3014-26. DOI: https://doi.org/10.1002/cncr.25827
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2023 Oncología Clínica
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
